Adrenergic Drugs and Vasopressors

• Adrenergic Receptor Subtypes and G-Protein Coupling: α1-adrenergic receptors (α1A, α1B, α1D subtypes) couple to Gq proteins, activating phospholipase C and increasing intracellular calcium to produce vasoconstriction and increased peripheral vascular resistance. α2-adrenergic receptors (α2A, α2B, α2C subtypes) couple to Gi proteins, decreasing cAMP and inhibiting norepinephrine release at presynaptic terminals; α2A activation in the locus coeruleus produces sedation and analgesia. β1-adrenergic receptors, localized predominantly on cardiac myocytes, couple to Gs proteins, activating adenylyl cyclase and increasing cAMP, which enhances inotropy (force of contraction), chronotropy (heart rate), and lusitropy (diastolic relaxation). β2-adrenergic receptors on vascular smooth muscle, bronchial smooth muscle, and skeletal muscle couple to Gs proteins, producing vasodilation, bronchodilation, and increased metabolic rate. The relative contribution of each receptor to an agent's overall effect is dose-dependent: at low doses, selective receptors dominate, whereas at higher doses, less selective binding occurs, explaining the biphasic hemodynamic responses observed with many drugs.

• Catecholamine Synthesis, Storage, Release, and Metabolism: Endogenous catecholamines (epinephrine, norepinephrine, dopamine) are synthesized from tyrosine through a multi-step pathway: tyrosine → L-DOPA (via tyrosine hydroxylase, rate-limiting) → dopamine → norepinephrine → epinephrine. Catecholamines are stored in vesicles within nerve terminals and the adrenal medulla, then released via exocytosis in response to nerve depolarization or hypoglycemia/stress. Termination of catecholamine action occurs through three mechanisms: (1) uptake-1 (norepinephrine transporter, NET), which recycles catecholamines back into nerve terminals for repackaging or metabolism; (2) uptake-2 (organic cation transporter, OCT), a lower-affinity system in extraneuronal tissues; and (3) enzymatic degradation by monoamine oxidase (MAO, intraneuronal) and catechol-O-methyltransferase (COMT, extraneuronal), producing inactive metabolites including metanephrine, normetanephrine, and vanillylmandelic acid (VMA). Cocaine and tricyclic antidepressants block NET, potentiating catecholamine effects. This reuptake mechanism explains why exogenous catecholamines have shorter durations of action than endogenous ones and why continuous infusions are required for sustained hemodynamic support.

• Dose-Dependent Receptor Selectivity and Hemodynamic Effects: The physiologic response to adrenergic agonists is profoundly dose-dependent due to differences in receptor affinities and tissue distribution. At very low doses, dopamine preferentially stimulates D1 and D2 dopaminergic receptors in renal and mesenteric vasculature, producing selective vasodilation ("renal-dose dopamine," though clinical benefit is debated). At intermediate doses, dopamine activates β1-adrenergic receptors on the heart, increasing contractility and heart rate. At high doses, dopamine and other catecholamines activate α1-adrenergic receptors, producing systemic vasoconstriction and increased afterload. Epinephrine demonstrates similar dose-dependency: at low doses, β2-mediated vasodilation predominates (resulting in decreased blood pressure); at intermediate doses, β1-mediated inotropy and chronotropy predominate; at high doses, α1-mediated vasoconstriction dominates, markedly increasing blood pressure and peripheral vascular resistance. This receptor hierarchy explains why the same drug can produce opposite hemodynamic effects depending on dosing and clinical context, and why dose titration to clinical endpoints (rather than fixed dosing) is essential.

• Shock Pathophysiology and the Rationale for Vasopressor Use: Shock is defined as inadequate tissue perfusion and oxygenation, resulting in cellular hypoxia and anaerobic metabolism. In distributive shock (e.g., sepsis), massive vasodilation and capillary leak result from endotoxin-mediated release of nitric oxide, prostaglandins, and cytokines, overwhelming endogenous catecholamine responsiveness. In cardiogenic shock, reduced cardiac output from myocardial dysfunction or mechanical obstruction necessitates augmentation of contractility and heart rate. In hypovolemic shock, sympathetic activation is initially compensatory, but exogenous catecholamines provide temporary support while definitive treatment (fluid resuscitation, hemorrhage control) is implemented. Vasopressors restore adequate mean arterial pressure (MAP) to maintain cerebral and coronary perfusion pressure (perfusion pressure = MAP – intracranial/right atrial pressure). The goal is to achieve sufficient perfusion pressure to restore aerobic metabolism and prevent ischemic injury to vital organs (brain, heart, kidneys, liver) while underlying pathology is addressed. However, excessive vasoconstriction can paradoxically worsen tissue perfusion by increasing afterload (in cardiogenic shock) or by causing regional ischemia in peripheral and splanchnic beds despite apparent normalization of systemic blood pressure—a critical distinction between "hemodynamic support" and "tissue perfusion."

• Tachyphylaxis and Receptor Desensitization: Prolonged exposure to adrenergic agonists causes receptor desensitization through several mechanisms, including β-arrestin binding (preventing G-protein coupling), phosphorylation of receptors by G-protein receptor kinases (GRK), internalization of receptors, and downregulation of receptor expression. This tachyphylaxis is particularly problematic with dopamine and dobutamine, requiring dose escalation over hours to days of continuous infusion. β-blockers can paradoxically worsen shock by blocking compensatory β-adrenergic responses but are also associated with improved long-term outcomes in sepsis if continued (though initiation during active shock is contraindicated). Understanding this temporal dynamic is critical for interpreting clinical responses and avoiding the trap of attributing hemodynamic deterioration solely to worsening underlying disease rather than drug-induced tachyphylaxis.

• Septic Shock: Sepsis (infection with organ dysfunction defined by SOFA score ≥2) progresses to septic shock when hypotension persists despite adequate fluid resuscitation (>30 mL/kg crystalloid in the first 3 hours), requiring vasopressor initiation. Septic shock is the most common indication for vasopressor use in intensive care, with mortality rates of 30–40% despite optimal care. The pathophysiology involves gram-negative endotoxin (LPS) or gram-positive superantigens triggering toll-like receptors (TLR4, TLR2) on macrophages and dendritic cells, releasing IL-1, TNF-α, and IL-6, which amplify the inflammatory cascade and upregulate inducible nitric oxide synthase (iNOS). Excessive nitric oxide production causes profound vasodilation and impaired vascular responsiveness to catecholamines. Additionally, sepsis impairs mitochondrial function, reducing the ability of tissues to utilize oxygen even when perfusion is restored. β-blockers (e.g., metoprolol) may improve outcomes in septic shock by reducing tachycardia and improving diastolic filling, though evidence is mixed.

• Cardiogenic Shock: Acute myocardial infarction (particularly anterior wall MI with extensive left ventricular necrosis), acute decompensated heart failure, myocarditis, and mechanical complications (acute mitral regurgitation, ventricular septal defect, free wall rupture) reduce cardiac output below 2.2 L/min/m² despite adequate filling pressures (pulmonary capillary wedge pressure >18 mmHg). Cardiogenic shock carries in-hospital mortality of 50% and requires both inotropic support (dobutamine, milrinone, low-dose epinephrine) to improve contractility and, often, vasopressor support (norepinephrine) to maintain coronary perfusion pressure. The β1-adrenergic inotropic effects of catecholamines increase myocardial oxygen consumption, which can precipitate further ischemia in the setting of acute MI; thus, rapid revascularization (PCI, thrombolytics) or mechanical support (intra-aortic balloon pump, ventricular assist device, extracorporeal membrane oxygenation) should be pursued in parallel with hemodynamic support. In heart failure, chronic β-adrenergic overstimulation contributes to progressive myocardial damage through cAMP-mediated calcium overload and oxidative stress, explaining why acute inotropic support is temporizing and why long-term β-blockade improves outcomes.

• Hypovolemic Shock: Hemorrhage, severe dehydration, and third-spacing of fluids reduce intravascular volume, triggering compensatory sympathetic activation and vasoconstriction. Vasopressors in hypovolemic shock are temporizing measures only and must be accompanied by rapid fluid and blood product administration (permissive hypotension in trauma patients, target MAP 50–65 mmHg, minimizes ongoing hemorrhage). Prolonged vasopressor use without adequate resuscitation leads to "shock spiral"—progressive cellular hypoxia, increased vascular permeability, ongoing fluid losses, and irreversible organ failure. The concept of "damage control" (in trauma) or "source control" (in sepsis) emphasizes that vasopressors buy time for definitive treatment but cannot substitute for it.

• Anaphylaxis: IgE-mediated mast cell and basophil degranulation releases histamine, tryptase, and leukotrienes, causing rapid onset of angioedema, bronchospasm, and profound vasodilation. Epinephrine is the first-line drug, with IM administration (0.3–0.5 mg of 1:1000 solution) preferred over IV in most cases to allow for controlled systemic absorption and repeated dosing if needed. IV epinephrine in anaphylaxis is reserved for refractory hypotension or cardiac arrest and requires extreme caution due to risk of coronary vasospasm and myocardial infarction.

• Perioperative Hypotension: Anesthesia-induced vasodilation and myocardial depression, blood loss, and inadequate fluid replacement necessitate vasopressor support in 10–50% of surgical cases depending on procedure type and patient factors. Phenylephrine is commonly used for acute hypotension in the operating room due to its rapid onset, easy titratability, and minimal tachycardia (pure α1 agonism).

• Resistant Hypotension in Specific Settings: Tricyclic antidepressant or cocaine overdose produces catecholamine excess initially but is followed by catecholamine depletion and refractoriness to exogenous catecholamines; in such cases, vasopressors may be ineffective or produce paradoxical responses. Cyanide poisoning impairs mitochondrial oxidative metabolism, rendering tissues unable to utilize oxygen; vasopressors are ineffective unless hydroxocobalamin (specific antidote) is administered. These scenarios emphasize the critical importance of treating underlying pathology rather than relying solely on hemodynamic support.

• Hypotension and Decreased Mean Arterial Pressure: Systolic blood pressure <90 mmHg, mean arterial pressure <65 mmHg, or a drop >40 mmHg from baseline defines hypotension in shock. The hemodynamic threshold for organ ischemia is pressure-dependent: the cerebral autoregulation range is approximately 50–150 mmHg MAP, meaning that in acute hypotension, cerebral perfusion fails below 50 mmHg. Renal autoregulation is maintained down to approximately 80 mmHg MAP; below this, acute kidney injury risk increases. Coronary perfusion pressure (aortic diastolic pressure – left ventricular end-diastolic pressure) must exceed 60 mmHg to perfuse the subendocardium during diastole; in severe hypotension or increased left ventricular pressure, subendocardial ischemia occurs first.

• Tachycardia and Arrhythmias: Sympathetic activation increases heart rate (>100 bpm typically), reducing diastolic filling time and exacerbating hemodynamic compromise, particularly in diastolic dysfunction or mitral stenosis. High doses of catecholamines, especially epinephrine and dopamine, can precipitate atrial fibrillation, ventricular tachycardia, or ventricular fibrillation through enhanced automaticity (increased cAMP-mediated calcium influx) and shortened action potential duration. Catecholamine-induced QT prolongation and torsades de pointes are particularly concerning in patients receiving QT-prolonging medications (fluoroquinolones, antipsychotics, antiarrhythmics). β1-adrenergic stimulation increases both heart rate and contractility (positive inotropism), but in the setting of myocardial ischemia, increased contractility increases myocardial oxygen consumption, potentially worsening ischemia.

• Altered Mental Status and Confusion: Cerebral hypoperfusion from shock produces restlessness, agitation, and progressive obtundation progressing to coma if perfusion is not restored. Interestingly, catecholamine excess (from endogenous release or exogenous administration) can also produce agitation and anxiety through α2-adrenergic and β-adrenergic effects on the central nervous system. High-dose epinephrine infusions can produce tremor, diaphoresis, and a sense of impending doom that mimics acute coronary syndrome.

• Cool, Clammy Skin and Peripheral Vasoconstriction: α1-adrenergic vasoconstriction of cutaneous arterioles causes pale, mottled skin (especially in extremities and abdomen) and reduces temperature differential between core and periphery. Capillary refill time (normal <2 seconds) becomes prolonged. In septic shock, particularly early "warm shock," skin may initially be warm due to vasodilation, but progression to "cold shock" with peripheral vasoconstriction indicates severe hypoperfusion.

• Oliguria and Acute Kidney Injury (AKI): Renal blood flow is autoregulated but decreases sharply when MAP drops below 80 mmHg. Prerenal azotemia develops within hours of hypotension, with fractional excretion of sodium (FENa) <1% in the absence of intrinsic renal disease. Acute tubular necrosis (ATN) develops if hypotension is prolonged or repeatedly interrupted, characterized by FENa >2% and muddy brown granular casts. Vasopressin (ADH) release and renin-angiotensin-aldosterone system (RAAS) activation in shock cause renal vasoconstriction and sodium reabsorption, partially offsetting the direct effect of reduced perfusion pressure.

• Lactic Acidosis: Inadequate tissue perfusion forces a shift from aerobic to anaerobic metabolism, producing lactate faster than the liver can clear it. Blood lactate >2 mmol/L indicates tissue hypoxia; lactate >

Cardiac toxicity (β1-mediated)

• Tachyarrhythmias: increased cAMP raises intracellular calcium and phase 4 depolarization slope, enhancing automaticity — atrial fibrillation, ventricular ectopy, and ventricular tachycardia. Dopamine causes substantially more arrhythmic events than norepinephrine in shock, which is why the Surviving Sepsis Campaign restricts dopamine to highly selected patients with bradycardia and low arrhythmia risk.
• Myocardial ischemia and demand infarction: increased heart rate, contractility, and wall stress raise myocardial oxygen consumption while tachycardia shortens diastolic coronary filling time. Epinephrine can also provoke coronary vasospasm, the reason IV epinephrine in anaphylaxis is reserved for arrest or refractory shock.
• Stress cardiomyopathy: catecholamine surge can produce apical ballooning (takotsubo), a classic mimic of anterior STEMI.

Perfusion-related toxicity (α1-mediated)

• Digital, limb, and mesenteric ischemia: excessive vasoconstriction can worsen tissue perfusion despite a normal MAP; monitor digits, capillary refill, and lactate rather than blood pressure alone.
• Extravasation necrosis: local α1 vasoconstriction produces blanching and skin necrosis. Antidote: local infiltration of the α-blocker phentolamine (topical nitroglycerin is an alternative). Central venous administration is preferred for prolonged infusion; brief peripheral use with close site monitoring is accepted while access is obtained.
• Increased afterload in cardiogenic shock: pure vasoconstrictors can lower stroke volume in a failing ventricle.

Metabolic and other effects

• β2 effects: hypokalemia (Na⁺/K⁺-ATPase-driven intracellular potassium shift), hyperglycemia, tremor, and a rise in lactate from aerobic glycolysis — a lactate elevation that does not signify hypoperfusion.
• Reflex bradycardia: phenylephrine's pure α1 pressor effect triggers baroreceptor-mediated vagal slowing.

Contraindications and dangerous interactions

• MAO inhibitors with indirect sympathomimetics (tyramine, ephedrine) → hypertensive crisis; cocaine or TCAs block NET reuptake and potentiate catecholamines.
• Nonselective β-blockade blunts epinephrine's β2 vasodilation, leaving unopposed α1 hypertension; conversely, α-blockade converts epinephrine's pressor response to a depressor one (epinephrine reversal).
• Pheochromocytoma: α-blockade must precede β-blockade. For β-blocker overdose the reversal agent is glucagon; for sympathomimetic toxicity, benzodiazepines.

• Norepinephrine is the first-line vasopressor in septic shock (Surviving Sepsis Campaign), targeting MAP ≥65 mmHg; its α1 effect dominates with enough β1 activity to preserve cardiac output. Vasopressin is added as the usual second agent to spare catecholamine dose, and epinephrine third. The common distractor is dopamine — more tachyarrhythmias, no survival advantage.
• Anaphylaxis: the single best next step is IM epinephrine into the anterolateral thigh, before antihistamines, corticosteroids, or IV fluids. Steroids and H1 blockers are adjuncts only and do not treat the airway or vasodilation.
• Cardiac arrest: epinephrine 1 mg IV/IO every 3–5 minutes per ACLS. In the shockable rhythms — ventricular fibrillation / pulseless VT — defibrillation comes first and epinephrine follows; in asystole/PEA give epinephrine as early as possible.
• Vasopressor extravasation → phentolamine infiltration. Recognize blanching around the IV site; this is the classic "antidote" question.
• Epinephrine reversal: after α-blockade (phentolamine, phenoxybenzamine), epinephrine's unopposed β2 vasodilation drops blood pressure. Related pearl: in pheochromocytoma, never β-block before α-blocking.
• Phenylephrine causes reflex bradycardia, not tachycardia — a pure α1 agonist ideal for perioperative hypotension or hypotension in a patient who cannot tolerate tachycardia. Isoproterenol is the mirror image: pure β agonist, tachycardia with a widened pulse pressure from β2 vasodilation.
• Dobutamine is an inotrope, not a pressor: β1 ≫ β2 stimulation can lower SVR and blood pressure; it is used for low-output cardiogenic shock and pharmacologic stress testing. Milrinone (PDE3 inhibitor) achieves the same inodilator effect without adrenergic receptors and accumulates in renal failure.
• "Renal-dose dopamine" does not prevent acute kidney injury — a persistent distractor. Likewise, vasopressors cannot substitute for volume in hemorrhagic or hypovolemic shock; source control and resuscitation are the definitive therapy.